Search clinical trials for: deferiprone

Total 60 results

Ain Shams University

Unknown

Role of Vitamin C to Augment Iron Chelation With DFP or DFX

Thalassemia Major | Iron Chelation | Vitamin c

Egypt
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission

Completed

Pharmacokinetic Study of Deferiprone in Paediatric Patients (DEEP-1)

Chronic Iron Overload

Italy, Cyprus, Egypt
ApoPharma

Completed

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Healthy

Canada
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Imperial College London

Completed

A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease (DeferipronPD)

Parkinson's Disease

United Kingdom
SocraTec R&D GmbH
SocraMetrics GmbH

Completed

Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

Bioequivalence

Germany
ApoPharma
Algorithme Pharma Inc

Completed

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

Healthy

Canada
Chiesi Canada Corp

Completed

Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children (START)

Iron Overload | Beta Thalassemia Major Anemia

Egypt, Indonesia
Children's Hospital of Philadelphia
ApoPharma

Approved for marketing

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Iron Overload

United States
ApoPharma

Completed

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload (TWICE)

Iron Overload Due to Repeated Red Blood Cell Transfusions

United States, Canada, Greece, Italy
Royal Brompton & Harefield NHS Foundation Trust
CORDA, The Heart Charity; Apotex Inc.; The Cooley's Anemia Foundation,; The UK...

Unknown

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

Beta-Thalassemia

Italy
Azienda Ospedaliera V. Cervello

Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

Beta-Thalassemia | Thalassemia Major

Italy
ApoPharma

Completed

A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

Friedreich's Ataxia

Belgium, France, Italy, Spain
CorMedix

Completed

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Contrast-Induced Acute Kidney Injury

United States
Rohan Dharmakumar
Cardio-theranostics LLC; Lipomed AG

Recruiting

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients (MIRON-DFP)

Acute Myocardial Infarction Type 1

United States
CorMedix

Withdrawn

Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent

Acute Kidney Injury
First Affiliated Hospital of Fujian Medical University

Recruiting

Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients

Aceruloplasminemia

China
University Hospital, Lille

Completed

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes (LymphoEnergy)

Parkinson's Disease | Amyotrophic Lateral Sclerosis | Iron Overload | Oxidative Stress

France
ApoPharma

Completed

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

Friedreich's Ataxia

Canada, Australia, Belgium, France, Italy, Spain
ApoPharma

Completed

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration (TIRCON-EXT)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom
University Hospital, Lille

Completed

Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease (FAIR-PARK-I)

Parkinson's Disease

France
Lipomed

Completed

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

Hemochromatosis

Egypt, Turkey
University Hospital, Bordeaux

Recruiting

Iron Chelation in the Prevention of Secondary Degeneration After Stroke (CHEL-IC)

Stroke

France
ApoPharma

Completed

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

Asymptomatic HIV Infection

South Africa
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Heart Diseases | Cardiovascular Diseases | Beta-Thalassemia

United States
ApoPharma

Completed

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

Sickle Cell Disease

Canada
Ospedale Microcitemico
Azienda Sanitaria Locale di Cagliari

Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major (DFODFPTM)

Iron Overload | Cardiomyopathy

Italy
Duke University

Recruiting

Ferritin and Iron Burden in SAH sIRB

Dementia | SAH

United States
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
Lipomed

Completed

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Hemochromatosis

Switzerland
ApoPharma
Food and Drug Administration (FDA)

Completed

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
ApoPharma

Terminated

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)

Iron Overload | Sickle Cell Disease | Other Anemias

United States, Turkey, United Kingdom, Egypt, Saudi Arabia, Brazil, Canada, Tunisia
Ain Shams University

Unknown

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

Beta-thalassemia | Serum Ferritin | Iron Chelation Therapy

Egypt
China Medical University Hospital

Completed

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

Beta-thalassemia Major
University Hospital, Lille
ApoPharma

Completed

Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (SAFEFAIRALS)

ALS (Amyotrophic Lateral Sclerosis) | Iron Overload

France
Ain Shams University

Unknown

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

Beta Thalassemia Major

Egypt
ApoPharma

Completed

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Prolonged QTc Interval

United States
Sheba Medical Center
Hadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...

Completed

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Myelodysplastic Syndrome With Low-grade Lesions | Iron Overload Due to Repeated Red Blood Cell Transfusions

Israel
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Renal Impairment

Canada
Chiesi Canada Corp

No longer available

Compassionate Use of Deferiprone in Patients With PKAN

Pantothenate Kinase-Associated Neurodegeneration
ApoPharma

Completed

Study of Parkinson's Early Stage With Deferiprone (SKY)

Parkinson's Disease

United Kingdom, France, Germany, Canada
University Hospital, Lille
Ministry of Health, France

Active, not recruiting

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis (FAIR-ALS II)

Amyotrophic Lateral Sclerosis

France
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

Hepatic Impairment

United States
ApoPharma

Completed

Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

HIV Infection

South Africa
ApoPharma

Completed

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

Iron Overload

Egypt, Indonesia, Malaysia
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
The University of Texas Health Science Center at...

Withdrawn

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

Mild Cognitive Impairment

United States
ApoPharma

Terminated

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Iron Overload | Sickle Cell Disease | Other Anemias

United States, United Kingdom, Egypt, Canada, Saudi Arabia

Search clinical trials for: deferiprone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations